The Priority Review

The stream · Daily digest

The stream: Saturday, November 14, 2026

1 brief, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 1

  1. Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026

    Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.

    Source: Company press release (PR Newswire), November 14, 2026